

# SUPPLEMENTARY MATERIALS

## Contents

S.1. Literature Search .....	3
The Keywords .....	3
The Search Results .....	3
Table S1. Results of systematic searches. ....	3
S.2. Assessment of Quality of Study .....	4
Table S2. The assessment of quality of study for cohort studies using Newcastle-Ottawa Scale (NOS) .....	4
Table S3. The assessment of quality of study for case-control studies using Newcastle-Ottawa Scale (NOS) .....	5
S.3. Summary of outcomes for full dose.....	7
Table S4. Summary of outcomes for full dose .....	7
S.4. Summary of outcomes for booster dose .....	11
Table S5. Summary of outcomes for booster dose .....	11
S.5. Summary of outcomes for booster vs full dose of the within 3 months or more model .	14
Table S6. Summary of outcomes for booster vs full dose of the within 3 months or more model .....	14
S.6. Summary of outcomes for booster vs full dose of the within 3 months model.....	16
Table S7. Summary of outcomes for booster vs full dose of the within 3 months model ..	16
S.8. Detailed Results of VE Estimates and VE Reduction of Full Dose .....	18
Table S9. Detailed results of VE estimates and VE reduction of full dose for any infection outcome .....	18
Table S10. Detailed results of VE estimates and VE reduction of full dose for severe infection outcome .....	28
Table S11. Detailed results of VE estimates and VE reduction of full dose for symptomatic infection outcome .....	34
S.9. Detailed Results of VE Estimates and VE Reduction of Booster Dose.....	43
Table S12. Detailed results of VE estimates and VE reduction of booster dose for any infection outcome .....	43
Table S13. Detailed results of VE estimates and VE reduction of booster dose for severe infection outcome .....	51
Table S14. Detailed results of VE estimates and VE reduction of booster dose for symptomatic infection outcome .....	56
S.10. Detailed Results of Meta-analyses for the 'Within 3 Months' Model .....	63
Table S15. Detailed Results of meta-analyses for within 3 months model .....	63

S.11. Detailed Results of Meta-analyses for the ‘Within 3 Months or More’ Model .....	65
Table S16. Detailed Results of meta-analyses for within 3 months or more model .....	65
S.12. Sensitivity Analyses for the ‘Within 3 Months’ Model.....	67
Figure S1. The result of leave-one-out sensitivity analyses for any infection endpoint in the ‘within 3 months’ model .....	67
Figure S2. The result of leave-one-out sensitivity analyses for severe infection endpoint in the ‘within 3 months’ model .....	68
Figure S3. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the ‘within 3 months’ model .....	69
S.13. Sensitivity Analyses for the ‘Within 3 Months or More’ Model.....	70
Figure S4. The result of leave-one-out sensitivity analyses for any infection endpoint in the ‘within 3 months or more’ model .....	70
Figure S5. The result of leave-one-out sensitivity analyses for severe infection endpoint in the ‘within 3 months or more’ model .....	71
Figure S6. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the ‘within 3 months or more’ model .....	72

## S.1. Literature Search

### The Keywords

#1 (SARS-CoV-2) OR (COVID-19)

#2 (Omicron) OR (B.1.1.529)

#3 (Vaccine) OR (Vaccination)

#4 (Vaccine efficacy) OR (Vaccine effectiveness)

### The Search Results

Table S1. Results of systematic searches.

<b>Database</b>	<b>Keywords</b>	<b>Search Result</b>	<b>Search-time</b>
PubMed	#1 AND #2 AND #3 AND #4	121	April 6 <sup>th</sup> , 2022
ScienceDirect	#1 AND #2 AND #3 AND #4	475	April 6 <sup>th</sup> , 2022
CENTRAL	#1 AND #2 AND #3 AND #4	2	April 6 <sup>th</sup> , 2022
Web of Science	#1 AND #2 AND #3 AND #4	61	April 6 <sup>th</sup> , 2022
Scopus	#1 AND #2 AND #3 AND #4	619	April 6 <sup>th</sup> , 2022
medRxiv	#1 AND #2 AND #3 AND #4	455	April 6 <sup>th</sup> , 2022
bioRxiv	#1 AND #2 AND #3 AND #4	312	April 6 <sup>th</sup> , 2022
Bibliographic search	-	19	April 6 <sup>th</sup> , 2022

## S.2. Assessment of Quality of Study

Table S2. The assessment of quality of study for cohort studies using Newcastle-Ottawa Scale (NOS)

<b>NOS of Cohort Study</b>					
<b>Components</b>	Hansen et al. (2021)	Abu-Raddad et al. (2022)	Monge et al., (2022)	Šmíd et al. (2022)	Fowlkes et al. (2022)
<b>Selection</b>					
Representativeness of the exposed cohort	*	*	*	*	*
Selection of the non-exposed cohort	*	*	*	*	*
Ascertainment of exposure	*	*	*	*	*
Demonstration that outcome of interest was not present at start of the study	*	*	-	-	-
<b>Comparability</b>					
Comparability of cohorts on the basis of design or analysis	*	**	*	*	*
<b>Exposure</b>					
Assessment of outcome	*	*	*	*	*
Enough follow-up time length for outcome to occur	*	*	*	*	*
Adequacy of follow-up of cohorts	*	*	*	*	*
<b>Study Quality</b>					
<b>Total Score</b>	8	9	7	7	7
<b>Interpretation</b>	Good	Good	Good	Good	Good

Table S3. The assessment of quality of study for case-control studies using Newcastle-Ottawa Scale (NOS)

NOS of Case-Control Study										
Components	Selection			Comparability		Exposure			Study Quality	
	Is the case definition adequate?	Representativeness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-response rate	Total Score	Interpretation
Buchan et al. (2021)	*	*	*	*	*	-	*	*	7	Good
Gray et al. (2021)	*	*	*	*	*	*	*	*	8	Good
Accorsi et al. (2022)	*	*	*	*	*	-	*	*	7	Good
Andrews et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Chemaitelly et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Collie et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Ferdinand et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Klein et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Lauring et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Natarajan et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Tartof et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Tenforde et al. (2022)	*	*	*	*	*	-	*	*	7	Good

Thompson et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Tseng et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Young-Xu et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Zambrano et al. (2022)	*	*	*	*	*	*	*	*	8	Good

### S.3. Summary of outcomes for full dose

Table S4. Summary of outcomes for full dose

Study	Endpoints	Vaccine	Study Design	Days Latitude	Follow-up Interval	SE	VE (95%CI)
Ferdinand et al., 2022	Severe infection	Mixture of mRNA	Case-control	60	0 to 2 months	8.163	71% (51% to 83%)
		Mixture of mRNA	Case-control	180	2 to 3 months	5.357	65% (53% to 74%)
		Mixture of mRNA	Case-control	240	3 to 4 months	8.418	58% (38% to 71%)
		Mixture of mRNA	Case-control	300	5+ months	2.806	54% (48% to 59%)
	Symptomatic Infection	Mixture of mRNA	Case-control	60	0 to 2 months	3.316	69% (62% to 75%)
		Mixture of mRNA	Case-control	180	2 to 3 months	2.551	50% (45% to 55%)
		Mixture of mRNA	Case-control	240	3 to 4 months	3.316	48% (41% to 54%)
		Mixture of mRNA	Case-control	300	5+ months	1.531	37% (34% to 40%)
Klein et al., 2022	Symptomatic infection (Age 16-17 years)	BNT162b2	Case-control	149	14 to 149 days	11.480	34% (8% to 53%)
		BNT162b2	Case-control	299	150+ days	12.245	-3% (-30% to 18%)
		BNT162b2	Case-control	149	14 to 149 days	6.888	45% (30% to 57%)
		BNT162b2	Case-control	299	150+ days	10.714	-2% (-25% to 17%)
		BNT162b2	Case-control	67	14 to 67 days	8.929	51% (30% to 65%)
Natarajan et al., 2022	Severe infection	AD26.COVS2S	Case-control	120	7 to 120 days	6.378	67% (52% to 77%)
		Mixture of mRNA	Case-control	120	7 to 120 days	3.571	78% (70% to 84%)
	Symptomatic Infection	AD26.COVS2S	Case-control	120	7 to 120 days	5.102	54% (43% to 63%)
		Mixture of mRNA	Case-control	120	7 to 120 days	2.041	79% (74% to 82%)
Tenforde et al., 2022	Severe infection	Mixture of mRNA	Case-control	256	256 days (median)	5.357	79% (66% to 87%)
Zambrano et al., 2022	Severe Infection	BNT162b2	Case-control	63	63 days (median)	5.357	90% (75% to 96%)
Accorsi et al., 2022*	Symptomatic Infection	BNT162b2	Case-control	240	14+ days	2.653	0% (-5% to 5%)
		mRNA-1273	Case-control	240	14+ days	2.679	13% (7% to 18%)
Andrews et al., 2022	Symptomatic Infection	ChAdOx1 nCov-19	Case-control	28	2 to 4 weeks	4.566	49% (39% to 57%)

		ChAdOx1 nCov-19	Case-control	70	5 to 9 weeks	4.209	34% (25% to 42%)
		ChAdOx1 nCov-19	Case-control	105	10 to 14 weeks	3.750	29% (21% to 36%)
		ChAdOx1 nCov-19	Case-control	140	15 to 19 weeks	2.168	18% (13% to 22%)
		ChAdOx1 nCov-19	Case-control	175	20 to 24 weeks	1.071	4% (2% to 6%)
		ChAdOx1 nCov-19	Case-control	210	25+ weeks	0.765	-3% (-4% to -1%)
		BNT162b2	Case-control	28	2 to 4 weeks	0.791	66% (64% to 67%)
		BNT162b2	Case-control	70	5 to 9 weeks	0.791	49% (47% to 50%)
		BNT162b2	Case-control	105	10 to 14 weeks	0.714	30% (29% to 32%)
		BNT162b2	Case-control	140	15 to 19 weeks	0.612	15% (14% to 17%)
		BNT162b2	Case-control	175	20 to 24 weeks	0.714	12% (10% to 13%)
		BNT162b2	Case-control	210	25+ weeks	0.893	9% (7% to 11%)
		mRNA-1273	Case-control	28	2 to 4 weeks	2.015	75% (71% to 79%)
		mRNA-1273	Case-control	70	5 to 9 weeks	2.270	53% (48% to 57%)
		mRNA-1273	Case-control	105	10 to 14 weeks	1.454	36% (33% to 38%)
		mRNA-1273	Case-control	140	15 to 19 weeks	1.071	25% (23% to 27%)
		mRNA-1273	Case-control	175	20 to 24 weeks	1.684	15% (12% to 18%)
		mRNA-1273	Case-control	210	25+ weeks	5.306	15% (4% to 25%)
Buchan et al., 2021	Symptomatic Infection	Mixture of mRNA	Case-control	59	7 to 59 days	5.357	36% (24% to 45%)
		Mixture of mRNA	Case-control	119	60 to 119 days	4.592	12% (3% to 21%)
		Mixture of mRNA	Case-control	179	120 to 179 days	3.571	15% (8% to 22%)
		Mixture of mRNA	Case-control	239	180 to 239 days	4.592	1% (-8% to 10%)
		Mixture of mRNA	Case-control	299	240+ days	8.673	2% (-17% to 17%)
		Mixture of mRNA	Case-control	59	7 to 59 days	50.000	55% (-106% to 90%)
		Mixture of mRNA	Case-control	119	60 to 119 days	37.755	37% (-71% to 77%)
		Mixture of mRNA	Case-control	179	120 to 179 days	9.184	75% (51% to 87%)
		Mixture of mRNA	Case-control	239	180 to 239 days	7.398	82% (62% to 91%)



		Mixture of mRNA	Case-control	299	240+ days	28.061	86% (-12% to 98%)
Chemaitelly et al., 2022	Symptomatic Infection	BNT162b2	Case-control	30	0 to 1 month	5.408	62% (50% to 71%)
		BNT162b2	Case-control	60	1 to 2 months	5.612	46% (34% to 56%)
		BNT162b2	Case-control	90	2 to 3 months	5.281	36% (25% to 46%)
		BNT162b2	Case-control	120	3 to 4 months	5.051	29% (18% to 38%)
		BNT162b2	Case-control	150	4 to 5 months	6.173	11% (-2% to 22%)
		BNT162b2	Case-control	180	5 to 6 months	3.980	14% (6% to 22%)
		BNT162b2	Case-control	210	6 to 7 months	3.546	10% (2% to 16%)
		BNT162b2	Case-control	240	7 to 8 months	3.852	-8% (-15% to 0%)
		BNT162b2	Case-control	270	8 to 9 months	3.801	2% (-6% to 9%)
		BNT162b2	Case-control	300	9 to 10 months	3.903	-18% (-26% to -10%)
		BNT162b2	Case-control	330	10 to 11 months	4.796	0% (-10% to 9%)
		BNT162b2	Case-control	360	11+ months	6.378	17% (3% to 28%)
		mRNA-1273	Case-control	120	1 to 3 months	12.194	45% (16% to 64%)
		mRNA-1273	Case-control	180	4 to 6 months	3.495	21% (14% to 27%)
mRNA-1273	Case-control	240	7+ months	3.444	-9% (-16% to -3%)		
Collie et al., 2022	Severe Infection	BNT162b2	Case-control	NR	14+ days	6.888	50% (35% to 62%)
	Symptomatic Infection	BNT162b2	Case-control	NR	0+ days	4.847	70% (59% to 78%)
Lauring et al., 2022	Severe Infection	Mixture of mRNA	Case-control	NR	7+ days	7.143	66% (49% to 77%)
Tartof et al., 2022		BNT162b2	Case-control	90	0 to 3 months	10.969	70% (41% to 84%)
		BNT162b2	Case-control	180	3 to 6 months	9.184	67% (44% to 80%)
		BNT162b2	Case-control	270	6+ months	5.102	68% (56% to 76%)
Symptomatic Infection	BNT162b2	Case-control	90	0 to 3 months	7.398	60% (43% to 72%)	
	BNT162b2	Case-control	180	3 to 6 months	7.653	38% (21% to 51%)	
	BNT162b2	Case-control	270	6+ months	4.592	41% (32% to 50%)	
Thompson et al., 2022	Positive Covid-19	Mixture of mRNA	Case-control	180	0 to 180 days	3.061	52% (46% to 58%)
		Mixture of mRNA	Case-control	360	180+ days	2.806	38% (32% to 43%)
		Mixture of mRNA	Case-control	179	0 to 179 days	6.378	81% (65% to 90%)

	Severe Infection	Mixture of mRNA	Case-control	359	180+ days	7.908	57% (39% to 70%)
Tseng et al., 2022	Positive Covid-19	mRNA-1273	Case-control	90	14 to 90 days	4.209	44% (35% to 52%)
		mRNA-1273	Case-control	180	91 to 180 days	3.469	24% (16% to 30%)
		mRNA-1273	Case-control	270	181 to 270 days	1.811	14% (10% to 17%)
		mRNA-1273	Case-control	360	270+ days	2.704	6% (0% to 11%)
	Severe Infection	mRNA-1273	Case-control	NR	14+ days	18.852	85% (23% to 97%)
Yong-Xu, 2022	Positive Covid-19	Mixture of mRNA	Case-control	NR	NR	2.551	25% (20% to 30%)
Fowlkes et al., 2022	Positive Covid-19	BNT162b2	Cohort	82	14 to 82 days	9.949	31% (9% to 48%)
		BNT162b2	Cohort	149	14 to 149 days	14.541	59% (22% to 79%)
		BNT162b2	Cohort	299	150+ days	29.847	62% (-28% to 89%)
Hansen et al., 2021	Positive Covid-19	BNT162b2	Cohort	30	27 to 28 days	12.806	55% (24% to 74%)
		BNT162b2	Cohort	60	31 to 60 days	15.944	16% (-21% to 42%)
		BNT162b2	Cohort	90	61 to 90 days	9.209	10% (-10% to 26%)
		BNT162b2	Cohort	150	91 to 150 days	9.133	-77% (-95% to -60%)
		mRNA-1273	Cohort	30	1 to 30 days	37.321	37% (-70% to 76%)
		mRNA-1273	Cohort	60	31 to 60 days	27.219	30% (-41% to 65%)
		mRNA-1273	Cohort	90	61 to 90 days	15.459	4% (-31% to 30%)
		mRNA-1273	Cohort	150	91 to 150 days	10.612	-39% (-62% to -20%)
Šmíd et al., 2022**	Positive Covid-19	Mixture	Cohort	60	0 to 2 months	0.510	43% (42% to 44%)
		Mixture	Cohort	120	2+ months	0.510	9% (8% to 10%)
	Severe Infection	Mixture	Cohort	60	0 to 2 months	7.143	45% (29% to 57%)
		Mixture	Cohort	120	2+ months	4.082	29% (21% to 37%)

\*Data of full dose in Accorsi et al., 2022 calculated from crude data of number of infected individuals

\*\*Smid et al., 2022 reports two full dose datasets, the one that exclude previous infection and with previous infection. We included the data that exclude previous infection for the analysis

\*Studies whose data of Days Latitude are only day 7 or below and NR are excluded from the meta-regression analysis.

## S.4. Summary of outcomes for booster dose

Table S5. Summary of outcomes for booster dose

Authors	Endpoints	Vaccine	Design	Days Latitude	Follow-up Interval	SE of VE	VE (95%CI)
Accorsi et al., 2022	Symptomatic Infection	BNT162b2	Case-control	30	7+ days	1.531	65% (62% to 68%)
		mRNA-1273	Case-control	30	7+ days	1.276	72% (69% to 74%)
Andrews et al., 2022	Symptomatic Infection	BNT162b2	Case-control	7	1 week	0.383	67% (66% to 68%)
		BNT162b2	Case-control	35	2 to 4 weeks	0.332	67% (67% to 68%)
		BNT162b2	Case-control	70	5 to 9 weeks	0.408	55% (54% to 56%)
		BNT162b2	Case-control	105	10+ week	5.867	46% (45% to 68%)
		ChAdOx1 nCov-19	Case-control	7	1 week	8.597	58% (38% to 71%)
		ChAdOx1 nCov-19	Case-control	35	2 to 4 weeks	5.230	56% (44% to 65%)
		ChAdOx1 nCov-19	Case-control	70	5 to 9 weeks	5.714	47% (34% to 57%)
		mRNA-1273	Case-control	7	1 week	1.301	64% (62% to 67%)
		mRNA-1273	Case-control	35	2 to 4 weeks	1.276	65% (62% to 67%)
Buchan et al., 2021	Severe infection	Mixture of mRNA	Case-control	6	0 to 6 days	6.633	91% (71% to 97%)
		Mixture of mRNA	Case-control	14	7+ days	2.806	95% (87% to 98%)
	Symptomatic Infection	Mixture of mRNA	Case-control	6	0 to 6 days	3.571	36% (29% to 43%)
		Mixture of mRNA	Case-control	14	7+ days	2.296	61% (56% to 65%)
Chemaitelly et al., 2022	Symptomatic Infection	BNT162b2	Case-control	7	1 week	7.015	16% (1% to 28%)
		BNT162b2	Case-control	21	2 to 3 weeks	6.097	53% (41% to 65%)
		BNT162b2	Case-control	42	4 to 5 weeks	2.781	57% (51% to 62%)
		BNT162b2	Case-control	63	6 to 7 weeks	3.138	46% (40% to 52%)
		BNT162b2	Case-control	84	8 to 9 weeks	4.694	38% (28% to 47%)
		BNT162b2	Case-control	105	10 to 11 weeks	5.051	44% (33% to 53%)
		mRNA-1273	Case-control	7	1 week	15.332	4% (-31% to 29%)

		mRNA-1273	Case-control	21	2 to 3 weeks	5.638	53% (41% to 63%)
		mRNA-1273	Case-control	42	4 to 5 weeks	6.097	55% (41% to 65%)
		mRNA-1273	Case-control	63	6+ weeks	8.597	39% (19% to 53%)
Ferdinand et al., 2022	Symptomatic Infection	Mixture of mRNA	Case-control	60	0 to 2 months	0.765	87% (85% to 88%)
		Mixture of mRNA	Case-control	180	2 to 3 months	0.765	81% (79% to 82%)
		Mixture of mRNA	Case-control	240	3 to 4 months	3.061	66% (59% to 71%)
		Mixture of mRNA	Case-control	300	5+ months	30.102	31% (-50% to 68%)
	Severe infection	Mixture of mRNA	Case-control	60	0 to 2 months	1.276	91% (88% to 93%)
		Mixture of mRNA	Case-control	180	2 to 3 months	1.276	88% (85% to 90%)
Mixture of mRNA		Case-control	240	4+ months	4.592	78% (67% to 85%)	
Gray et al., 2021	Positive Covid-19	Ad26.CO2	Case-control	14	0 to 13 days	3.567	32% (25% to 39%)
		Ad26.CO2	Case-control	28	14 to 27 days	3.674	14% (7% to 22%)
		Ad26.CO2	Case-control	87	27 to 28 days	6.857	6% (-6% to 20%)
	Severe Infection	Ad26.CO2	Case-control	13	0 to 13 days	13.265	93% (47% to 99%)
		Ad26.CO2	Case-control	27	14 to 27 days	11.224	81% (49% to 93%)
Klein et al., 2022	Symptomatic Infection (Age 5-11 years)	BNT162b2	Case-control	67	14 to 67 days	8.929	51% (30% to 65%)
	Symptomatic Infection (Age 12-15 years)	BNT162b2	Case-control	149	14 to 149 days	6.888	45% (30% to 57%)
		BNT162b2	Case-control	299	150+ days	10.714	-2% (-25% to 17%)
	Symptomatic infection (Age 16-17 years)	BNT162b2	Case-control	149	14 to 149 days	11.480	34% (8% to 53%)
BNT162b2		Case-control	299	150+ days	12.245	-3% (-30% to 18%)	
Lauring et al., 2022	Severe infection	Mixture of mRNA	Case-control	N/A	7+ days	4.337	86% (75% to 92%)
Monge et al., 2022	Positive Covid-19	Mixture	Case-control	34	7 to 34 days	0.561	51% (50% to 52%)
Natarajan et al., 2022	Symptomatic Infection	Mixture	Case-control	120	7 to 120 days	0.510	83% (82% to 84%)

	Severe infection	Mixture	Case-control	120	7 to 120 days	0.765	90% (88% to 91%)
Tartof et al., 2022	Severe infection	BNT162b2	Case-control	90	0 to 3 months	2.296	89% (83% to 92%)
		BNT162b2	Case-control	180	3 to 5 months	10.459	90% (57% to 98%)
	Symptomatic Infection	BNT162b2	Case-control	90	6+ months	2.296	78% (73% to 82%)
		BNT162b2	Case-control	180	270+ days	14.286	48% (13% to 69%)
Tenforde et al., 2022	Severe infection	Mixture of mRNA	Case-control	60	60 days (median)	2.296	94% (88% to 97%)
Thompson et al., 2022	Symptomatic Infection	Mixture of mRNA	Case-control	N/A	14+ days	1.276	82% (79% to 84%)
	Severe infection	Mixture of mRNA	Case-control	N/A	14+ days	3.571	90% (80% to 94%)
Tseng et al., 2022	Severe infection	mRNA-1273	Case-control	N/A	14+ days	6.046	99% (76% to 100%)
	Positive Covid-19	mRNA-1273	Case-control	60	14 to 60 days	0.944	72% (70% to 74%)
		mRNA-1273	Case-control	120	60+ days	3.342	51% (44% to 57%)
Yong-Xu, 2022	Severe infection	Mixture of mRNA	Case-control	N/A	NR	2.296	91% (85% to 94%)
Hansen et al., 2021	Positive Covid-19	BNT162b2	Cohort	30	1 to 30 days	10.179	55% (31% to 70%)
Šmíd et al., 2022	Symptomatic Infection	Mixture	Cohort	60	60 to 120 days	0.255	56% (55% to 56%)
		Mixture	Cohort	120	120+ days	1.020	21% (19% to 23%)
	Severe infection	Mixture	Cohort	60	60 to 120 days	5.357	87% (73% to 94%)
		Mixture	Cohort	120	120+ days	2.041	79% (75% to 83%)

\*Studies whose data of Days Latitude are N/A or less than 7 days are excluded from the analysis.

## S.5. Summary of outcomes for booster vs full dose of the within 3 months or more model

Table S6. Summary of outcomes for booster vs full dose of the within 3 months or more model

Authors	Outcomes	Design	Vaccine	VED (95%CI)	SE of VED
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	BNT162b2	50.6% (50.18% to 51.02%)	0.213
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	52.7% (51.53% to 53.87%)	0.597
Abu-Raddad et al., 2022	Severe infection	Cohort	BNT162b2	23.5% (20.57% to 26.43%)	1.497
Accorsi et al., 2022	Symptomatic Infection	Case-control	BNT162b2	64.9% (64.34% to 65.46%)	0.284
Accorsi et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	59.5% (58.81% to 60.19%)	0.352
Andrews et al., 2022	Symptomatic Infection	Cohort	ChAdOx1 nCov-19	27.29% (16.16% to 38.43%)	5.68
Andrews et al., 2022	Symptomatic Infection	Cohort	BNT162b2	28.15% (26.5% to 29.79%)	0.841
Andrews et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	33.96% (28.34% to 39.59%)	2.869
Buchan et al., 2021	Symptomatic Infection	Case-control	mixture of mRNA	35.85% (24.81% to 46.89%)	5.633
Buchan et al., 2021	Severe infection	Case-control	mixture of mRNA	24.21% (-33.37% to 81.79%)	29.377
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	6% (-14.52% to 26.51%)	10.466
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	BNT162b2	9.01% (-23.82% to 41.83%)	16.748
Ferdinand et al., 2022	symptomatic Infection	Case-control	mixture of mRNA	22.33% (16.9% to 27.77%)	2.774

Hansen et al., 2022	Positive Covid-19	Cohort	BNT162b2	78.54% (53.26% to 103.81%)	12.895
Klein et al., 2022	symptomatic Infection	Case-control	BNT162b2	41.7% (21.43% to 61.98%)	10.345
Lauring et al., 2022	Severe infection	Case-control	mixture of mRNA	2% (-4.88% to 8.88%)	3.512
Natarajan et al., 2022	Symptomatic Infection	Case-control	mixture of mRNA	29% (26.41% to 31.59%)	1.321
Natarajan et al., 2022	Severe infection	Case-control	mixture of mRNA	17.5% (14.87% to 20.13%)	1.342
Šmíd et al., 2022	Severe infection	Case-control	Mixture	46% (35.35% to 56.65%)	5.436
Šmíd et al., 2022	Positive Covid-19	Case-control	Mixture	1.5% (-3.94% to 6.94%)	2.774
Tartof et al., 2022	Symptomatic Infection	Case-control	BNT162b2	33% (24.98% to 41.02%)	4.09
Tartof et al., 2022	Severe infection	Case-control	BNT162b2	19% (-0.18% to 38.18%)	9.788
Tenforde et al., 2022	Severe infection	Case-control	mixture of mRNA	15% (12.88% to 17.12%)	1.082
Thompson et al., 2022	Severe infection	Case-control	mixture of mRNA	9% (-1.9% to 19.9%)	5.563
Thompson et al., 2022	Positive Covid-19	Case-control	mixture of mRNA	30% (25.07% to 34.93%)	2.516
Tseng et al., 2022	severe infection	Case-control	mRNA-1273	14.7% (7.49% to 21.91%)	3.676
Tseng et al., 2022	Positive Covid-19	Case-control	mRNA-1273	27.6% (20.4% to 34.8%)	3.674
Yong-Xu et al., 2022	Positive Covid-19	Case-control	mixture of mRNA	21% (20.14% to 21.86%)	0.437

## S.6. Summary of outcomes for booster vs full dose of the within 3 months model

Table S7. Summary of outcomes for booster vs full dose of the within 3 months model

Authors	Outcomes	Design	Vaccine	VED (95% CI)	SE_diff
Andrews et al., 2022	Symptomatic Infection	Cohort	ChAdOx1 nCov-19	16.11% (2.41 to 29.82%)	6.99
Andrews et al., 2022	Symptomatic Infection	Cohort	BNT162b2	17.64% (16.24 to 19.05%)	0.717
Andrews et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	16.52% (12.45 to 20.59%)	2.075
Buchan et al., 2021	Symptomatic Infection	Case-control	mixture of mRNA	27.25% (-5.06 to 59.56%)	16.485
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	BNT162b2	0% (-6.08 to 6.08%)	3.103
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	33% (-21.38 to 87.38%)	27.744
Tartof et al., 2022	Symptomatic Infection	Case-control	BNT162b2	-5.72% (-19.59 to 8.15%)	7.077
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	BNT162b2	-7.7% (-38.69 to 23.29%)	15.812
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	2% (-8.26 to 12.26%)	5.234
Natarajan et al., 2022	Symptomatic Infection	Case-control	mixture of mRNA	27.6% (19.15 to 36.06%)	4.314
Klein et al., 2022	symptomatic Infection	Case-control	BNT162b2	33% (23.82 to 42.18%)	4.683
Ferdinand et al., 2022	symptomatic Infection	Case-control	mixture of mRNA	19% (-2.97 to 40.97%)	11.207
Buchan et al., 2021	Severe infection	Case-control	mixture of mRNA	-3.1% (-6.29 to 0.09%)	1.625



Lauring et al., 2022	Severe infection	Case-control	mixture of mRNA	-3.5% (-6.45 to -0.55%)	1.507
Tartof et al., 2022	Severe infection	Case-control	BNT162b2	42% (32 to 52%)	5.102
Smid et al., 2022	Severe infection	Case-control	Mixture	3.5% (0.17 to 6.83%)	1.697
Abu-Raddad et al., 2022	Severe infection	Cohort	BNT162b2	50.6% (48.35 to 52.85%)	1.148
Natarajan et al., 2022	Severe infection	Case-control	mixture of mRNA	23.5% (7.7 to 39.3%)	8.061
Tenforde et al., 2022	Severe infection	Case-control	mixture of mRNA	52.7% (46.4 to 59%)	3.214
Hansen et al., 2022	Positive Covid-19	Cohort	BNT162b2	29% (18.95 to 39.05%)	5.127
Tseng et al., 2022	Positive Covid-19	Case-control	mRNA-1273	17.5% (7.26 to 27.74%)	5.225
Monge et al., 2022	Positive Covid-19	Case-control	mRNA-1273	15% (3.58 to 26.42%)	5.828
Monge et al., 2022	Positive Covid-19	Design	BNT162b2	30% (12.93 to 47.07%)	8.71
Smid et al., 2022	Positive Covid-19	Cohort	Mixture	22.33% (16.11 to 28.56%)	3.176

## S.8. Detailed Results of VE Estimates and VE Reduction of Full Dose

Table S9. Detailed results of VE estimates and VE reduction of full dose for any infection outcome

Variable	Overall	Report																											
Results	<p>Mixed-Effects Model (k = 93; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc -434.8900 869.7800 875.7800 883.3125 876.0558</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 741.3064 (SE = 118.5740) tau (square root of estimated tau<sup>2</sup> value): 27.2269 I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.50% H<sup>2</sup> (unaccounted variability / sampling variability): 199.94 R<sup>2</sup> (amount of heterogeneity accounted for): 9.91%</p> <p>Test for Residual Heterogeneity: QE(df = 91) = 7954.7133, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2): F(df1 = 1, df2 = 91) = 8.9517, p-val = 0.0036</p> <p>Model Results:</p> <table> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>50.1200</td> <td>6.2132</td> <td>8.0667</td> <td>91</td> <td>&lt;.0001</td> <td>37.7783</td> <td>62.4618</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.0985</td> <td>0.0329</td> <td>-2.9919</td> <td>91</td> <td>0.0036</td> <td>-0.1640</td> <td>-0.0331</td> <td>**</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	50.1200	6.2132	8.0667	91	<.0001	37.7783	62.4618	***	Days	-0.0985	0.0329	-2.9919	91	0.0036	-0.1640	-0.0331	**	<p>R<sup>2</sup> = 9.91%</p> <p>VE estimate (%): 50.12 (37.78 to 62.46), p:&lt;.0001</p> <p>VE reduction estimate (% per month): -2.955 (-4.92 to -0.993), p:0.0036</p> <p>VE (%) = 50.12 - 0.0985 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	50.1200	6.2132	8.0667	91	<.0001	37.7783	62.4618	***																					
Days	-0.0985	0.0329	-2.9919	91	0.0036	-0.1640	-0.0331	**																					

Reg Plot										
Variable	Ad26.COV2.S									
Results	<p>Number of studies combined: k = 2</p> <table border="1" data-bbox="358 1085 1120 1181"> <thead> <tr> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Random effects model</td> <td>59.94 [-22.34; 142.22]</td> <td>9.26</td> <td>0.0685</td> </tr> </tbody> </table> <p>Quantifying heterogeneity:  <math>\tau^2 = 0.0051</math>; <math>\tau = 0.0715</math>  <math>I^2 = 60.5\%</math> [0.0%; 90.8%]; <math>H = 1.59</math> [1.00; 3.30]</p>	VE	95%-CI	t	p-value	Random effects model	59.94 [-22.34; 142.22]	9.26	0.0685	<p><math>I^2 = 60.5\%</math>  VE estimate (%):  59.94 (-22.34 to 142.22), p:0.0685  VE reduction estimate (% per month):  N/A</p>
VE	95%-CI	t	p-value							
Random effects model	59.94 [-22.34; 142.22]	9.26	0.0685							

	Test of heterogeneity: Q d.f. p-value 2.53 1 0.1114																																						
Reg Plot	N/A																																						
Variable	<b>BNT162b2</b>																																						
Results	Mixed-Effects Model (k = 38; tau^2 estimator: REML)  <table> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-171.6450</td> <td>343.2899</td> <td>349.2899</td> <td>354.0405</td> <td>350.0399</td> </tr> </table> tau^2 (estimated amount of residual heterogeneity): 717.3130 (SE = 183.0239) tau (square root of estimated tau^2 value): 26.7827 I^2 (residual heterogeneity / unaccounted variability): 99.45% H^2 (unaccounted variability / sampling variability): 181.89 R^2 (amount of heterogeneity accounted for): 24.08%  Test for Residual Heterogeneity: QE(df = 36) = 1269.8612, p-val < .0001  Test of Moderators (coefficient 2): F(df1 = 1, df2 = 36) = 10.4159, p-val = 0.0027  Model Results:  <table> <tr> <td></td> <td>estimate</td> <td>se</td> <td>tval</td> <td>df</td> <td>pval</td> <td>ci.lb</td> <td>ci.ub</td> <td></td> </tr> <tr> <td>intrcpt</td> <td>54.6182</td> <td>9.3902</td> <td>5.8165</td> <td>36</td> <td>&lt;.0001</td> <td>35.5739</td> <td>73.6624</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1607</td> <td>0.0498</td> <td>-3.2274</td> <td>36</td> <td>0.0027</td> <td>-0.2617</td> <td>-0.0597</td> <td>**</td> </tr> </table>	logLik	deviance	AIC	BIC	AICc	-171.6450	343.2899	349.2899	354.0405	350.0399		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	54.6182	9.3902	5.8165	36	<.0001	35.5739	73.6624	***	Days	-0.1607	0.0498	-3.2274	36	0.0027	-0.2617	-0.0597	**	R^2 = 24.08% VE estimate (%): 54.62 (35.57 to 73.66), p:<.0001 VE reduction estimate (% per month): -4.821 (-7.851 to -1.791), p:0.0027  VE (%) = 54.6182 - 0.1607 day
logLik	deviance	AIC	BIC	AICc																																			
-171.6450	343.2899	349.2899	354.0405	350.0399																																			
	estimate	se	tval	df	pval	ci.lb	ci.ub																																
intrcpt	54.6182	9.3902	5.8165	36	<.0001	35.5739	73.6624	***																															
Days	-0.1607	0.0498	-3.2274	36	0.0027	-0.2617	-0.0597	**																															

Reg Plot												
Variable	ChAdOx1 nCov-19											
Results	<p>Mixed-Effects Model (k = 6; tau<sup>2</sup> estimator: REML)</p> <table border="0"> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-9.6120</td> <td>19.2241</td> <td>25.2241</td> <td>23.3830</td> <td>49.2241</td> </tr> </table> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 2.8159 (SE = 4.7880)  tau (square root of estimated tau<sup>2</sup> value): 1.6781  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 46.23%  H<sup>2</sup> (unaccounted variability / sampling variability): 1.86  R<sup>2</sup> (amount of heterogeneity accounted for): 99.22%</p>	logLik	deviance	AIC	BIC	AICc	-9.6120	19.2241	25.2241	23.3830	49.2241	<p>R<sup>2</sup> = 99.22%  VE estimate (%):  56.03 (47.81 to 64.25), p:&lt;.0001  VE reduction estimate (% per month):  -8.532 (-9.978 to -7.089), p:&lt;.0001    VE (%) = 56.0307 - 0.2844 day</p>
logLik	deviance	AIC	BIC	AICc								
-9.6120	19.2241	25.2241	23.3830	49.2241								


Test for Residual Heterogeneity:  
QE(df = 4) = 6.9972, p-val = 0.1360

Test of Moderators (coefficient 2):  
F(df1 = 1, df2 = 4) = 269.3835, p-val < .0001

Model Results:

	estimate	se	tval	df	pval	ci.lb	ci.ub	
intrcpt	56.0307	2.9616	18.9192	4	<.0001	47.8081	64.2534	***
Days	-0.2844	0.0173	-16.4129	4	<.0001	-0.3326	-0.2363	***


Reg Plot



Variable

Mixture


Results	<p>Mixed-Effects Model (k = 4; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance    AIC    BIC    AICc  -7.5277  15.0555  21.0555  17.1349  45.0555</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity):  99.6973 (SE = 115.8024)  tau (square root of estimated tau<sup>2</sup> value):  9.9849  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 88.68%  H<sup>2</sup> (unaccounted variability / sampling variability): 8.84  R<sup>2</sup> (amount of heterogeneity accounted for):  63.29%</p> <p>Test for Residual Heterogeneity:  QE(df = 2) = 23.7186, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 2) = 6.1503, p-val = 0.1313</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>69.3531</td> <td>16.5628</td> <td>4.1873</td> <td>2</td> <td>0.0526</td> <td>-1.9107</td> <td>140.6170</td> </tr> <tr> <td>Days</td> <td>-0.4259</td> <td>0.1717</td> <td>-2.4800</td> <td>2</td> <td>0.1313</td> <td>-1.1649</td> <td>0.3130</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub	intrcpt	69.3531	16.5628	4.1873	2	0.0526	-1.9107	140.6170	Days	-0.4259	0.1717	-2.4800	2	0.1313	-1.1649	0.3130	<p>R<sup>2</sup> = 63.29%</p> <p>VE estimate (%):  69.35 (-1.91 to 140.62), p:0.0526</p> <p>VE reduction estimate (% per month):  -12.777 (-34.947 to 9.39), p:0.1313</p> <p>VE (%) = 69.3531 - 0.4259 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																			
intrcpt	69.3531	16.5628	4.1873	2	0.0526	-1.9107	140.6170																			
Days	-0.4259	0.1717	-2.4800	2	0.1313	-1.1649	0.3130																			

Reg Plot												
Variable	Mixture of mRNA vaccines											
Results	<p>Mixed-Effects Model (k = 25; tau<sup>2</sup> estimator: REML)</p> <table border="0"> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-108.0914</td> <td>216.1827</td> <td>222.1827</td> <td>225.5892</td> <td>223.4459</td> </tr> </table> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 613.3061 (SE = 201.1280)  tau (square root of estimated tau<sup>2</sup> value): 24.7650  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 97.50%  H<sup>2</sup> (unaccounted variability / sampling variability): 40.05  R<sup>2</sup> (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity:  QE(df = 23) = 628.4139, p-val &lt; .0001</p>	logLik	deviance	AIC	BIC	AICc	-108.0914	216.1827	222.1827	225.5892	223.4459	<p>R<sup>2</sup> = 0%  VE estimate (%):  62.47 (36.03 to 88.91), p:&lt;.0001  VE reduction estimate (% per month):  -1.536 (-5.142 to 2.067), p:0.3868</p> <p>VE (%) = 62.4733 - 0.0512 day</p>
logLik	deviance	AIC	BIC	AICc								
-108.0914	216.1827	222.1827	225.5892	223.4459								



	<p>Test of Moderators (coefficient 2):  <math>F(df1 = 1, df2 = 23) = 0.7783, p\text{-val} = 0.3868</math></p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>62.4733</td> <td>12.7813</td> <td>4.8879</td> <td>23</td> <td>&lt;.0001</td> <td>36.0331</td> <td>88.9135</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.0512</td> <td>0.0581</td> <td>-0.8822</td> <td>23</td> <td>0.3868</td> <td>-0.1714</td> <td>0.0689</td> <td></td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	62.4733	12.7813	4.8879	23	<.0001	36.0331	88.9135	***	Days	-0.0512	0.0581	-0.8822	23	0.3868	-0.1714	0.0689		
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	62.4733	12.7813	4.8879	23	<.0001	36.0331	88.9135	***																					
Days	-0.0512	0.0581	-0.8822	23	0.3868	-0.1714	0.0689																						
Reg Plot																													
Variable	mRNA-1273																												
Results	Mixed-Effects Model (k = 18; tau^2 estimator: REML) <table border="1"> <thead> <tr> <th>logLik</th> <th>deviance</th> <th>AIC</th> <th>BIC</th> <th>AICc</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		logLik	deviance	AIC	BIC	AICc						$R^2 = 42.33\%$ VE estimate (%):																
logLik	deviance	AIC	BIC	AICc																									


<p>-71.7588 143.5177 149.5177 151.8354 151.5177</p> <p>tau^2 (estimated amount of residual heterogeneity): 346.2541 (SE = 140.5909)  tau (square root of estimated tau^2 value): 18.6079  I^2 (residual heterogeneity / unaccounted variability): 98.12%  H^2 (unaccounted variability / sampling variability): 53.13  R^2 (amount of heterogeneity accounted for): 42.33%</p> <p>Test for Residual Heterogeneity:  QE(df = 16) = 344.1080, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 16) = 9.7084, p-val = 0.0067</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.up</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>51.8048</td> <td>10.5712</td> <td>4.9006</td> <td>16</td> <td>0.0002</td> <td>29.3949</td> <td>74.2146</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1780</td> <td>0.0571</td> <td>-3.1158</td> <td>16</td> <td>0.0067</td> <td>-0.2991</td> <td>-0.0569</td> <td>**</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.up		intrcpt	51.8048	10.5712	4.9006	16	0.0002	29.3949	74.2146	***	Days	-0.1780	0.0571	-3.1158	16	0.0067	-0.2991	-0.0569	**	<p>51.8 (29.39 to 74.21), p:0.0002  VE reduction estimate (% per month):  -5.34 (-8.973 to -1.707), p:0.0067</p> <p>VE (%) = 51.8048 - 0.178 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.up																					
intrcpt	51.8048	10.5712	4.9006	16	0.0002	29.3949	74.2146	***																				
Days	-0.1780	0.0571	-3.1158	16	0.0067	-0.2991	-0.0569	**																				



Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two reports ( $k = 2$ ).

Table S10. Detailed results of VE estimates and VE reduction of full dose for severe infection outcome

Variable	overall																												
Results	<p>Mixed-Effects Model (k = 15; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc -54.6842 109.3685 115.3685 117.0633 118.0351</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 235.8090 (SE = 108.9539) tau (square root of estimated tau<sup>2</sup> value): 15.3561 I<sup>2</sup> (residual heterogeneity / unaccounted variability): 88.26% H<sup>2</sup> (unaccounted variability / sampling variability): 8.52 R<sup>2</sup> (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity: QE(df = 13) = 145.4933, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2): F(df1 = 1, df2 = 13) = 0.1494, p-val = 0.7053</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>68.2800</td> <td>9.0585</td> <td>7.5377</td> <td>13</td> <td>&lt;.0001</td> <td>48.7104</td> <td>87.8497</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.0178</td> <td>0.0460</td> <td>-0.3865</td> <td>13</td> <td>0.7053</td> <td>-0.1172</td> <td>0.0817</td> <td></td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	68.2800	9.0585	7.5377	13	<.0001	48.7104	87.8497	***	Days	-0.0178	0.0460	-0.3865	13	0.7053	-0.1172	0.0817		<p>R<sup>2</sup> = 0%</p> <p>VE estimate (%): 68.28 (48.71 to 87.85), p:&lt;.0001</p> <p>VE reduction estimate (% per month): -0.534 (-3.516 to 2.451), p:0.7053</p> <p>VE (%) = 68.28 - 0.0178 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	68.2800	9.0585	7.5377	13	<.0001	48.7104	87.8497	***																					
Days	-0.0178	0.0460	-0.3865	13	0.7053	-0.1172	0.0817																						

Reg Plot		
Variable	Ad26.COV2.S	
Results	VE estimate (%): 67 (52 to 77)	VE estimate (%): 67 (52 to 77) VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 4; tau <sup>2</sup> estimator: REML)  tau <sup>2</sup> (estimated amount of residual heterogeneity): 37.0869 (SE = 110.2998) tau (square root of estimated tau <sup>2</sup> value): 6.0899 I <sup>2</sup> (residual heterogeneity / unaccounted variability): 33.62% H <sup>2</sup> (unaccounted variability / sampling variability): 1.51 R <sup>2</sup> (amount of heterogeneity accounted for): 63.40%	R <sup>2</sup> = 63.4% VE estimate (%): 89.88 (50.39 to 129.38), p:0.0103 VE reduction estimate (% per month): -2.715 (-9.177 to 3.747), p:0.2125  VE (%) = 89.8824 - 0.0905 day


Test for Residual Heterogeneity:  
 QE(df = 2) = 2.9009, p-val = 0.2345

Test of Moderators (coefficient 2):  
 F(df1 = 1, df2 = 2) = 3.2663, p-val = 0.2125

Model Results:

	estimate	se	tval	df	pval	ci.lb	ci.ub
intrcpt	89.8824	9.1794	9.7918	2	0.0103	50.3867	129.3781 *
Days	-0.0905	0.0501	-1.8073	2	0.2125	-0.3059	0.1249

Reg Plot




Variable ChAdOx1 nCov-19

Results N/A

Reg Plot N/A

Variable	mixture											
Results	<p>Number of studies combined: k = 2</p> <table> <thead> <tr> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Random effects model</td> <td>35.9262 [-64.8036; 136.6561]</td> <td>4.53</td> <td>0.1383</td> </tr> </tbody> </table> <p>Quantifying heterogeneity:  <math>\tau^2 = 94.1599</math>; <math>\tau = 9.7036</math>  <math>I^2 = 73.6\%</math> [0.0%; 94.0%]; <math>H = 1.94</math> [1.00; 4.10]</p> <p>Test of heterogeneity:  Q d.f. p-value  3.78 1 0.0518</p>	VE	95%-CI	t	p-value	Random effects model	35.9262 [-64.8036; 136.6561]	4.53	0.1383	$I^2 = 73.6\%$ VE estimate (%): 35.9262 (-64.8036 to 136.6561), p: 0.1383 VE reduction estimate (% per month): N/A		
VE	95%-CI	t	p-value									
Random effects model	35.9262 [-64.8036; 136.6561]	4.53	0.1383									
Reg Plot	N/A											
Variable	Mixture of mRNA											
Results	<p>Mixed-Effects Model (k = 8; <math>\tau^2</math> estimator: REML)</p> <table> <thead> <tr> <th>logLik</th> <th>deviance</th> <th>AIC</th> <th>BIC</th> <th>AICc</th> </tr> </thead> <tbody> <tr> <td>-22.0809</td> <td>44.1618</td> <td>50.1618</td> <td>49.5370</td> <td>62.1618</td> </tr> </tbody> </table> <p><math>\tau^2</math> (estimated amount of residual heterogeneity): 59.2136 (SE = 53.6906)  <math>\tau</math> (square root of estimated <math>\tau^2</math> value): 7.6950  <math>I^2</math> (residual heterogeneity / unaccounted variability): 66.06%  <math>H^2</math> (unaccounted variability / sampling variability): 2.95  <math>R^2</math> (amount of heterogeneity accounted for): 38.23%</p> <p>Test for Residual Heterogeneity:  QE(df = 6) = 18.3740, p-val = 0.0054</p> <p>Test of Moderators (coefficient 2):</p>	logLik	deviance	AIC	BIC	AICc	-22.0809	44.1618	50.1618	49.5370	62.1618	$R^2 = 38.23\%$ VE estimate (%): 83.9 (62.22 to 105.58), p:<.0001 VE reduction estimate (% per month): -2.229 (-5.061 to 0.603), p:0.1023  VE (%) = 83.8956 - 0.0743 day
logLik	deviance	AIC	BIC	AICc								
-22.0809	44.1618	50.1618	49.5370	62.1618								


	<p>F(df1 = 1, df2 = 6) = 3.7116, p-val = 0.1023</p> <p>Model Results:</p> <pre> estimate   se   tval df  pval  ci.lb  ci.ub intrcpt 83.8956 8.8601 9.4689 6 &lt;.0001 62.2156 105.5755 *** Days    -0.0743 0.0386 -1.9266 6 0.1023 -0.1687 0.0201 </pre>	
Reg Plot	 <p>The regression plot displays Vaccine Effectiveness on the y-axis (ranging from 40 to 90) against Time in days on the x-axis (ranging from 0 to 350). A blue line represents the linear regression fit, which shows a slight downward trend. A grey shaded area around the line indicates the confidence interval. Several data points are plotted as circles, with some being larger than others, indicating varying weights or significance.</p>	
Variable	mRNA-1273	
Results	N/A	
Reg Plot	N/A	



Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report ( $k = 2$ ). Cell is denoted as **orange** if the result is from a report ( $k = 1$ ) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies ( $k = 0$ ).

Table S11. Detailed results of VE estimates and VE reduction of full dose for symptomatic infection outcome

Variable	overall																												
Results	<p>Mixed-Effects Model (k = 59; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc                      -255.0308 510.0617 516.0617 522.1908 516.5145</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 380.0117 (SE = 77.7305)                      tau (square root of estimated tau<sup>2</sup> value): 19.4939                      I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.08%                      H<sup>2</sup> (unaccounted variability / sampling variability): 108.75                      R<sup>2</sup> (amount of heterogeneity accounted for): 37.44%</p> <p>Test for Residual Heterogeneity:                      QE(df = 57) = 3743.4931, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):                      F(df1 = 1, df2 = 57) = 29.5771, p-val &lt; .0001</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>58.2061</td> <td>5.9668</td> <td>9.7551</td> <td>57</td> <td>&lt;.0001</td> <td>46.2579</td> <td>70.1543</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1734</td> <td>0.0319</td> <td>-5.4385</td> <td>57</td> <td>&lt;.0001</td> <td>-0.2372</td> <td>-0.1095</td> <td>***</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	58.2061	5.9668	9.7551	57	<.0001	46.2579	70.1543	***	Days	-0.1734	0.0319	-5.4385	57	<.0001	-0.2372	-0.1095	***	<p>R<sup>2</sup> = 37.44%</p> <p>VE estimate (%):                      58.21 (46.26 to 70.15), p:&lt;.0001</p> <p>VE reduction estimate (% per month):                      -5.202 (-7.116 to -3.285), p:&lt;.0001</p> <p>VE (%) = 58.2061 - 0.1734 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	58.2061	5.9668	9.7551	57	<.0001	46.2579	70.1543	***																					
Days	-0.1734	0.0319	-5.4385	57	<.0001	-0.2372	-0.1095	***																					

Reg Plot		
Variable	Ad26.COVS.S	
Results	VE estimate (%): 54 (43 to 63)	VE estimate (%): 54 (43 to 63) VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 27; tau <sup>2</sup> estimator: REML)  logLik   deviance   AIC   BIC   AICc -102.4504   204.9008   210.9008   214.5574   212.0437  tau <sup>2</sup> (estimated amount of residual heterogeneity):   185.0191 (SE = 60.1933) tau (square root of estimated tau <sup>2</sup> value):   13.6022	R <sup>2</sup> = 64.37% VE estimate (%): 58.38 (46.09 to 70.67), p:<.0001 VE reduction estimate (% per month): -5.91 (-7.761 to -4.056), p:<.0001  VE (%) = 58.3787 - 0.197 day

	<p>I<sup>2</sup> (residual heterogeneity / unaccounted variability): 98.50%  H<sup>2</sup> (unaccounted variability / sampling variability): 66.78  R<sup>2</sup> (amount of heterogeneity accounted for): 64.37%</p> <p>Test for Residual Heterogeneity:  QE(df = 25) = 760.6262, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 25) = 43.1650, p-val &lt; .0001</p> <p>Model Results:</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;"></th> <th style="text-align: right;">estimate</th> <th style="text-align: right;">se</th> <th style="text-align: right;">tval</th> <th style="text-align: right;">df</th> <th style="text-align: right;">pval</th> <th style="text-align: right;">ci.lb</th> <th style="text-align: right;">ci.ub</th> <th style="text-align: right;"></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td style="text-align: right;">58.3787</td> <td style="text-align: right;">5.9674</td> <td style="text-align: right;">9.7829</td> <td style="text-align: right;">25</td> <td style="text-align: right;">&lt;.0001</td> <td style="text-align: right;">46.0886</td> <td style="text-align: right;">70.6687</td> <td style="text-align: right;">***</td> </tr> <tr> <td>Days</td> <td style="text-align: right;">-0.1970</td> <td style="text-align: right;">0.0300</td> <td style="text-align: right;">-6.5700</td> <td style="text-align: right;">25</td> <td style="text-align: right;">&lt;.0001</td> <td style="text-align: right;">-0.2587</td> <td style="text-align: right;">-0.1352</td> <td style="text-align: right;">***</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	58.3787	5.9674	9.7829	25	<.0001	46.0886	70.6687	***	Days	-0.1970	0.0300	-6.5700	25	<.0001	-0.2587	-0.1352	***	
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	58.3787	5.9674	9.7829	25	<.0001	46.0886	70.6687	***																					
Days	-0.1970	0.0300	-6.5700	25	<.0001	-0.2587	-0.1352	***																					

Reg Plot												
Variable	ChAdOx1 nCov-19											
Results	<p>Mixed-Effects Model (k = 6; tau<sup>2</sup> estimator: REML)</p> <table border="0"> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-9.6120</td> <td>19.2241</td> <td>25.2241</td> <td>23.3830</td> <td>49.2241</td> </tr> </table> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 2.8159 (SE = 4.7880)  tau (square root of estimated tau<sup>2</sup> value): 1.6781  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 46.23%  H<sup>2</sup> (unaccounted variability / sampling variability): 1.86  R<sup>2</sup> (amount of heterogeneity accounted for): 99.22%</p> <p>Test for Residual Heterogeneity:</p>	logLik	deviance	AIC	BIC	AICc	-9.6120	19.2241	25.2241	23.3830	49.2241	<p>R<sup>2</sup> = 99.22%  VE estimate (%):  56.03 (47.81 to 64.25), p:&lt;.0001  VE reduction estimate (% per month):  -8.532 (-9.978 to -7.089), p:&lt;.0001</p> <p>VE (%) = 56.0307 - 0.2844 day</p>
logLik	deviance	AIC	BIC	AICc								
-9.6120	19.2241	25.2241	23.3830	49.2241								


QE(df = 4) = 6.9972, p-val = 0.1360

Test of Moderators (coefficient 2):  
 F(df1 = 1, df2 = 4) = 269.3835, p-val < .0001

Model Results:

	estimate	se	tval	df	pval	ci.lb	ci.ub	
intrcpt	56.0307	2.9616	18.9192	4	<.0001	47.8081	64.2534	***
Days	-0.2844	0.0173	-16.4129	4	<.0001	-0.3326	-0.2363	***

Reg Plot



Variable **mixture**

Results N/A

Reg Plot N/A

Variable	Mixture of mRNA																									
Results	<p>Mixed-Effects Model (k = 15; tau^2 estimator: REML)</p> <p>logLik deviance AIC BIC AICc -63.2346 126.4692 132.4692 134.1641 135.1359</p> <p>tau^2 (estimated amount of residual heterogeneity): 829.6853 (SE = 371.9081) tau (square root of estimated tau^2 value): 28.8043 I^2 (residual heterogeneity / unaccounted variability): 97.99% H^2 (unaccounted variability / sampling variability): 49.87 R^2 (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity: QE(df = 13) = 477.2669, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2): F(df1 = 1, df2 = 13) = 0.4370, p-val = 0.5201</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>55.6158</td> <td>19.2264</td> <td>2.8927</td> <td>13</td> <td>0.0126</td> <td>14.0797</td> <td>97.1519 *</td> </tr> <tr> <td>Days</td> <td>-0.0631</td> <td>0.0954</td> <td>-0.6611</td> <td>13</td> <td>0.5201</td> <td>-0.2693</td> <td>0.1431</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub	intrcpt	55.6158	19.2264	2.8927	13	0.0126	14.0797	97.1519 *	Days	-0.0631	0.0954	-0.6611	13	0.5201	-0.2693	0.1431	<p>R^2 = 0%</p> <p>VE estimate (%): 55.62 (14.08 to 97.15), p:0.0126</p> <p>VE reduction estimate (% per month): -1.893 (-8.079 to 4.293), p:0.5201</p> <p>VE (%) = 55.6158 - 0.0631 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																			
intrcpt	55.6158	19.2264	2.8927	13	0.0126	14.0797	97.1519 *																			
Days	-0.0631	0.0954	-0.6611	13	0.5201	-0.2693	0.1431																			

Reg Plot		
Variable	mRNA-1273	
Results	<p>Mixed-Effects Model (k = 10; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc  -28.3074 56.6147 62.6147 62.8531 68.6147</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 57.4425 (SE = 34.3197)  tau (square root of estimated tau<sup>2</sup> value): 7.5791  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 92.72%  H<sup>2</sup> (unaccounted variability / sampling variability): 13.75  R<sup>2</sup> (amount of heterogeneity accounted for): 89.96%</p> <p>Test for Residual Heterogeneity:</p>	<p>R<sup>2</sup> = 89.96%</p> <p>VE estimate (%):  76.11 (62.22 to 90), p:&lt;.0001</p> <p>VE reduction estimate (% per month):  -9.558 (-12.09 to -7.029), p:&lt;.0001</p> <p>VE (%) = 76.1092 - 0.3186 day</p>



QE(df = 8) = 91.5273, p-val < .0001


Test of Moderators (coefficient 2):

F(df1 = 1, df2 = 8) = 75.8955, p-val < .0001

Model Results:

	estimate	se	tval	df	pval	ci.lb	ci.ub	
intrcpt	76.1092	6.0235	12.6354	8	<.0001	62.2191	89.9994	***
Days	-0.3186	0.0366	-8.7118	8	<.0001	-0.4030	-0.2343	***

Reg Plot





Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ). Cell is denoted as **orange** if the result is from a report ( $k = 1$ ) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies ( $k = 0$ ).

## S.9. Detailed Results of VE Estimates and VE Reduction of Booster Dose

Table S12. Detailed results of VE estimates and VE reduction of booster dose for any infection outcome


Variable	Overall	Report																											
Results	<p>Mixed-Effects Model (k = 52; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc                      -230.1926 460.3852 466.3852 472.1213 466.9070</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 542.6083 (SE = 115.2483)                      tau (square root of estimated tau<sup>2</sup> value): 23.2940                      I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.86%                      H<sup>2</sup> (unaccounted variability / sampling variability): 710.84                      R<sup>2</sup> (amount of heterogeneity accounted for): 1.18%</p> <p>Test for Residual Heterogeneity:                      QE(df = 50) = 8970.2627, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):                      F(df1 = 1, df2 = 50) = 2.7243, p-val = 0.1051</p> <p>Model Results:</p> <table> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>66.0370</td> <td>5.3345</td> <td>12.3792</td> <td>50</td> <td>&lt;.0001</td> <td>55.3223</td> <td>76.7517</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.0769</td> <td>0.0466</td> <td>-1.6505</td> <td>50</td> <td>0.1051</td> <td>-0.1706</td> <td>0.0167</td> <td></td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	66.0370	5.3345	12.3792	50	<.0001	55.3223	76.7517	***	Days	-0.0769	0.0466	-1.6505	50	0.1051	-0.1706	0.0167		<p>R<sup>2</sup> = 0%</p> <p>VE estimate (%):                      66.04 (55.32 to 76.75), p:&lt;.0001</p> <p>VE reduction estimate (% per month):                      -2.307 (-5.118 to 0.501), p:0.1051</p> <p>VE (%) = 66.037 - 0.0769 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	66.0370	5.3345	12.3792	50	<.0001	55.3223	76.7517	***																					
Days	-0.0769	0.0466	-1.6505	50	0.1051	-0.1706	0.0167																						

Reg Plot		
Variable	Ad26.COVS.S	
Results	<p>Mixed-Effects Model (k = 5; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance    AIC    BIC    AICc  -15.0520 30.1039 36.1039 33.3997 60.1039</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 1254.1640 (SE = 1086.8963)  tau (square root of estimated tau<sup>2</sup> value): 35.4142  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 97.44%  H<sup>2</sup> (unaccounted variability / sampling variability): 39.13  R<sup>2</sup> (amount of heterogeneity accounted for): 11.79%</p> <p>Test for Residual Heterogeneity:  QE(df = 3) = 55.1021, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 3) = 1.5795, p-val = 0.2978</p>	<p>R<sup>2</sup> = 11.79%  VE estimate (%):  69.16 (-13.52 to 151.85), p:0.0762  VE reduction estimate (% per month):  -22.359 (-78.981 to 34.26), p:0.2978</p> <p>VE (%) = 69.1648 - 0.7453 day</p>

	<p>Model Results:</p> <pre> estimate   se   tval df  pval   ci.lb   ci.ub intrcpt 69.1648 25.9815 2.6621 3 0.0762 -13.5200 151.8496 . Days    -0.7453 0.5931 -1.2568 3 0.2978 -2.6327 1.1420 </pre>	
Reg Plot		
Variable	BNT162b2	
Results	<p>Mixed-Effects Model (k = 20; tau<sup>2</sup> estimator: REML)</p> <pre> logLik deviance   AIC   BIC   AICc -78.0335 156.0670 162.0670 164.7381 163.7812 </pre> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 282.9738 (SE = 107.4060)  tau (square root of estimated tau<sup>2</sup> value): 16.8218  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.63%  H<sup>2</sup> (unaccounted variability / sampling variability): 270.53  R<sup>2</sup> (amount of heterogeneity accounted for): 36.53%</p> <p>Test for Residual Heterogeneity:</p>	<p>R<sup>2</sup> = 36.53%  VE estimate (%):  69.79 (54.94 to 84.65), p:&lt;.0001  VE reduction estimate (% per month):  -5.442 (-8.988 to -1.893), p:0.0047  VE (%) = 69.7933 - 0.1814 day</p>

	<p>QE(df = 18) = 1907.8760, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 18) = 10.3822, p-val = 0.0047</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>69.7933</td> <td>7.0722</td> <td>9.8687</td> <td>18</td> <td>&lt;.0001</td> <td>54.9352</td> <td>84.6513</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1814</td> <td>0.0563</td> <td>-3.2221</td> <td>18</td> <td>0.0047</td> <td>-0.2996</td> <td>-0.0631</td> <td>**</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	69.7933	7.0722	9.8687	18	<.0001	54.9352	84.6513	***	Days	-0.1814	0.0563	-3.2221	18	0.0047	-0.2996	-0.0631	**	
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	69.7933	7.0722	9.8687	18	<.0001	54.9352	84.6513	***																					
Days	-0.1814	0.0563	-3.2221	18	0.0047	-0.2996	-0.0631	**																					
Reg Plot																													
Variable	ChAdOx1																												
Results	<p>Number of studies combined: k = 2</p> <table border="1"> <thead> <tr> <th></th> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Random effects model</td> <td>51.4480</td> <td>[-4.9677; 107.8637]</td> <td>11.59</td> <td>0.0548</td> </tr> </tbody> </table> <p>Quantifying heterogeneity:  tau<sup>2</sup> = 9.6042; tau = 3.0991; I<sup>2</sup> = 24.2%; H = 1.15</p>		VE	95%-CI	t	p-value	Random effects model	51.4480	[-4.9677; 107.8637]	11.59	0.0548	<p>I<sup>2</sup> = 24.2%</p> <p>VE estimate (%):  51.4480 (-4.9677 to 107.8637), p:  0.0548</p> <p>VE reduction estimate (% per month):  N/A</p>																	
	VE	95%-CI	t	p-value																									
Random effects model	51.4480	[-4.9677; 107.8637]	11.59	0.0548																									

	Test of heterogeneity: Q d.f. p-value 1.32 1 0.2506																									
Reg Plot	N/A																									
Variable	Mixture																									
Results	Mixed-Effects Model (k = 7; tau^2 estimator: REML)  logLik deviance AIC BIC AICc -23.6424 47.2849 53.2849 52.1132 77.2849  tau^2 (estimated amount of residual heterogeneity): 744.5094 (SE = 474.1033) tau (square root of estimated tau^2 value): 27.2857 I^2 (residual heterogeneity / unaccounted variability): 99.94% H^2 (unaccounted variability / sampling variability): 1581.11 R^2 (amount of heterogeneity accounted for): 0.00%  Test for Residual Heterogeneity: QE(df = 5) = 3493.4528, p-val < .0001  Test of Moderators (coefficient 2): F(df1 = 1, df2 = 5) = 0.0968, p-val = 0.7683  Model Results:  <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>58.2918</td> <td>28.7750</td> <td>2.0258</td> <td>5</td> <td>0.0986</td> <td>-15.6768</td> <td>132.2603</td> </tr> <tr> <td>Days</td> <td>0.0921</td> <td>0.2960</td> <td>0.3111</td> <td>5</td> <td>0.7683</td> <td>-0.6689</td> <td>0.8531</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub	intrcpt	58.2918	28.7750	2.0258	5	0.0986	-15.6768	132.2603	Days	0.0921	0.2960	0.3111	5	0.7683	-0.6689	0.8531	R^2 = 0% VE estimate (%): 58.29 (-15.68 to 132.26), p:0.0986 VE reduction estimate (% per month): 2.763 (-20.067 to 25.593), p:0.7683  VE (%) = 58.2918 + 0.0921 day
	estimate	se	tval	df	pval	ci.lb	ci.ub																			
intrcpt	58.2918	28.7750	2.0258	5	0.0986	-15.6768	132.2603																			
Days	0.0921	0.2960	0.3111	5	0.7683	-0.6689	0.8531																			

Reg Plot												
Variable	Mixture of mRNA											
Results	<p>Mixed-Effects Model (k = 10; tau<sup>2</sup> estimator: REML)</p> <table border="0"> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-32.5356</td> <td>65.0712</td> <td>71.0712</td> <td>71.3095</td> <td>77.0712</td> </tr> </table> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 148.4871 (SE = 81.8958)  tau (square root of estimated tau<sup>2</sup> value): 12.1855  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 98.22%  H<sup>2</sup> (unaccounted variability / sampling variability): 56.20  R<sup>2</sup> (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity:  QE(df = 8) = 215.9954, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 8) = 1.3832, p-val = 0.2734</p> <p>Model Results:</p>	logLik	deviance	AIC	BIC	AICc	-32.5356	65.0712	71.0712	71.3095	77.0712	<p>R<sup>2</sup> = 0%  VE estimate (%):  88.23 (72.01 to 104.46), p:&lt;.0001  VE reduction estimate (% per month):  -1.68 (-4.971 to 1.614), p:0.2734</p> <p>VE (%) = 88.2341 - 0.056 day</p>
logLik	deviance	AIC	BIC	AICc								
-32.5356	65.0712	71.0712	71.3095	77.0712								




	<pre> estimate  se  tval df  pval  ci.lb  ci.ub intrcpt  88.2341  7.0370  12.5386  8 &lt;.0001  72.0068  104.4614 *** Days     -0.0560  0.0476  -1.1761  8  0.2734  -0.1657  0.0538 </pre>	
Reg Plot		
Variable	mRNA-1273	
Results	<p>Mixed-Effects Model (k = 8; tau<sup>2</sup> estimator: REML)</p> <pre> logLik deviance  AIC  BIC  AICc -22.9728  45.9455  51.9455  51.3208  63.9455 </pre> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 94.7994 (SE = 65.0811)  tau (square root of estimated tau<sup>2</sup> value): 9.7365  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 95.56%  H<sup>2</sup> (unaccounted variability / sampling variability): 22.54  R<sup>2</sup> (amount of heterogeneity accounted for): 1.43%</p> <p>Test for Residual Heterogeneity:  QE(df = 6) = 78.7042, p-val &lt; .0001</p>	<p>R<sup>2</sup> = 1.43%  VE estimate (%):  66.54 (49.43 to 83.65), p:&lt;.0001  VE reduction estimate (% per month):  -3.717 (-12.579 to 5.145), p:0.3444</p> <p>VE (%) = 66.5414 - 0.1239 day</p>

	<p>Test of Moderators (coefficient 2):  <math>F(df1 = 1, df2 = 6) = 1.0529, p\text{-val} = 0.3444</math></p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>66.5414</td> <td>6.9927</td> <td>9.5158</td> <td>6</td> <td>&lt;.0001</td> <td>49.4308</td> <td>83.6519</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1239</td> <td>0.1207</td> <td>-1.0261</td> <td>6</td> <td>0.3444</td> <td>-0.4193</td> <td>0.1715</td> <td></td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	66.5414	6.9927	9.5158	6	<.0001	49.4308	83.6519	***	Days	-0.1239	0.1207	-1.0261	6	0.3444	-0.4193	0.1715		
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	66.5414	6.9927	9.5158	6	<.0001	49.4308	83.6519	***																					
Days	-0.1239	0.1207	-1.0261	6	0.3444	-0.4193	0.1715																						
Reg Plot	<p>The regression plot displays Vaccine Effectiveness on the y-axis (ranging from 40 to 80) against Time in days on the x-axis (ranging from 0 to 125). A blue line represents the linear regression fit, showing a slight downward trend. A grey shaded area around the line indicates the confidence interval. Several data points are plotted as open circles, with some points showing higher effectiveness than the regression line predicts.</p>																												

Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ).

Table S13. Detailed results of VE estimates and VE reduction of booster dose for severe infection outcome

Variable	overall																												
Results	<p>Mixed-Effects Model (k = 12; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc                      -30.9074 61.8147 67.8147 68.7225 71.8147</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 13.4208 (SE = 9.8845)                      tau (square root of estimated tau<sup>2</sup> value): 3.6634                      I<sup>2</sup> (residual heterogeneity / unaccounted variability): 75.90%                      H<sup>2</sup> (unaccounted variability / sampling variability): 4.15                      R<sup>2</sup> (amount of heterogeneity accounted for): 38.93%</p> <p>Test for Residual Heterogeneity:                      QE(df = 10) = 32.6589, p-val = 0.0003</p> <p>Test of Moderators (coefficient 2):                      F(df1 = 1, df2 = 10) = 6.3464, p-val = 0.0304</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>93.9648</td> <td>2.5418</td> <td>36.9678</td> <td>10</td> <td>&lt;.0001</td> <td>88.3013</td> <td>99.6283</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.0539</td> <td>0.0214</td> <td>-2.5192</td> <td>10</td> <td>0.0304</td> <td>-0.1015</td> <td>-0.0062</td> <td>*</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	93.9648	2.5418	36.9678	10	<.0001	88.3013	99.6283	***	Days	-0.0539	0.0214	-2.5192	10	0.0304	-0.1015	-0.0062	*	<p>R<sup>2</sup> = 38.93%</p> <p>VE estimate (%):                      93.96 (88.3 to 99.63), p&lt;.0001</p> <p>Decrease (% per month):                      -1.617 (-3.045 to -0.186), p: &lt;.0001</p> <p>VE (%) = 93.9648 - 0.0539 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	93.9648	2.5418	36.9678	10	<.0001	88.3013	99.6283	***																					
Days	-0.0539	0.0214	-2.5192	10	0.0304	-0.1015	-0.0062	*																					

Reg Plot										
Variable	Ad26.COVS.S									
Results	<p>Number of studies combined: k = 2</p> <table border="1" data-bbox="376 847 1503 922"> <thead> <tr> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Random effects model</td> <td>86.0069 [10.8212; 161.1926]</td> <td>14.53</td> <td>0.0437</td> </tr> </tbody> </table> <p>Quantifying heterogeneity: tau<sup>2</sup> = 0; tau = 0; I<sup>2</sup> = 0.0%; H = 1.00</p> <p>Test of heterogeneity: Q d.f. p-value 0.48 1 0.4898</p>	VE	95%-CI	t	p-value	Random effects model	86.0069 [10.8212; 161.1926]	14.53	0.0437	<p>I<sup>2</sup> = 0% VE estimate (%): 86.0069 (10.8212 to 161.1926), p: 0.0437 VE reduction estimate (% per month): N/A</p>
VE	95%-CI	t	p-value							
Random effects model	86.0069 [10.8212; 161.1926]	14.53	0.0437							
Reg Plot	N/A									
Variable	BNT162b2									
Results	<p>Number of studies combined: k = 2</p> <table border="1" data-bbox="376 1358 1503 1391"> <thead> <tr> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	VE	95%-CI	t	p-value					<p>I<sup>2</sup> = 0% VE estimate (%):</p>
VE	95%-CI	t	p-value							

	<p>Random effects model 89.0460 [86.3850; 91.7069] 425.20 0.0015</p> <p>Quantifying heterogeneity: tau<sup>2</sup> = 0; tau = 0; I<sup>2</sup> = 0.0%; H = 1.00</p> <p>Test of heterogeneity: Q d.f. p-value 0.01 1 0.9256</p>	<p>89.0460 (86.3850 to 91.7069), p:0.0015 VE reduction estimate (% per month): N/A</p>
Reg Plot	N/A	
Variable	ChAdOx1 nCov-19	
Results	N/A	
Reg Plot	N/A	
Variable	mixture	
Results	<p>Mixed-Effects Model (k = 3; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc -3.4703 6.9405 12.9405 6.9405 36.9405</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 58.1247 (SE = 85.5599) tau (square root of estimated tau<sup>2</sup> value): 7.6240 I<sup>2</sup> (residual heterogeneity / unaccounted variability): 96.07% H<sup>2</sup> (unaccounted variability / sampling variability): 25.47 R<sup>2</sup> (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity: QE(df = 1) = 25.4703, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2): F(df1 = 1, df2 = 1) = 0.0467, p-val = 0.8645</p> <p>Model Results:</p> <p>estimate se tval df pval ci.lb ci.ub</p>	<p>R<sup>2</sup> = 0% VE estimate (%): 89.34 (-157.54 to 336.22), p:0.1363 VE reduction estimate (% per month): -1.17 (-69.903 to 67.566), p:0.8645</p> <p>VE (%) = 89.3373 - 0.039 day</p>

	<pre> intrcpt 89.3373 19.4298 4.5979 1 0.1363 -157.5421 336.2167 Days    -0.0390 0.1803 -0.2160 1 0.8645 -2.3301 2.2522 </pre>	
Reg Plot		
Variable	Mixture of mRNA	
Results	<p>Mixed-Effects Model (k = 5; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc  -7.1849 14.3698 20.3698 17.6656 44.3698</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 1.7452 (SE = 5.1685)  tau (square root of estimated tau<sup>2</sup> value): 1.3210  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 27.20%  H<sup>2</sup> (unaccounted variability / sampling variability): 1.37  R<sup>2</sup> (amount of heterogeneity accounted for): 91.43%</p> <p>Test for Residual Heterogeneity:  QE(df = 3) = 4.1131, p-val = 0.2495</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 3) = 9.7430, p-val = 0.0524</p>	<p>R<sup>2</sup> = 91.43%  VE estimate (%):  95.26 (89.19 to 101.34), p:&lt;.0001  VE reduction estimate (% per month):  -1.434 (-2.895 to 0.027), p:0.0524</p> <p>VE (%) = 95.2629 - 0.0478 day</p>

	<p>Model Results:</p> <pre> estimate   se   tval df  pval  ci.lb  ci.ub intrcpt  95.2629  1.9087  49.9093  3 &lt;.0001  89.1885  101.3373 *** Days     -0.0478  0.0153  -3.1214  3  0.0524  -0.0965  0.0009 . </pre>	
Reg Plot		
Variable	mRNA-1273	
Results	VE: 99.2% (76.3% to 100%)	VE estimate (%): 99.2% (76.3% to 100%) VE reduction estimate (% per month): N/A
Reg Plot	N/A	

Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report ( $k = 2$ ). Cell is denoted as **orange** if the result is from a report ( $k = 1$ ) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies ( $k = 0$ ).

Table S14. Detailed results of VE estimates and VE reduction of booster dose for symptomatic infection outcome


Variable	overall																												
Results	<p>Mixed-Effects Model (k = 32; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance AIC BIC AICc                      -129.3988 258.7975 264.7975 269.0011 265.7206</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 297.8935 (SE = 84.8558)                      tau (square root of estimated tau<sup>2</sup> value): 17.2596                      I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.81%                      H<sup>2</sup> (unaccounted variability / sampling variability): 517.13                      R<sup>2</sup> (amount of heterogeneity accounted for): 15.68%</p> <p>Test for Residual Heterogeneity:                      QE(df = 30) = 6592.3798, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):                      F(df1 = 1, df2 = 30) = 8.9309, p-val = 0.0055</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>65.0327</td> <td>5.1151</td> <td>12.7138</td> <td>30</td> <td>&lt;.0001</td> <td>54.5863</td> <td>75.4791</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.1286</td> <td>0.0430</td> <td>-2.9885</td> <td>30</td> <td>0.0055</td> <td>-0.2164</td> <td>-0.0407</td> <td>**</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	65.0327	5.1151	12.7138	30	<.0001	54.5863	75.4791	***	Days	-0.1286	0.0430	-2.9885	30	0.0055	-0.2164	-0.0407	**	<p>R<sup>2</sup> = 15.68%</p> <p>VE estimate (%):                      65.03 (54.59 to 75.48), p:&lt;.0001</p> <p>VE reduction estimate (% per month):                      -3.858 (-6.492 to -1.221), p:0.0055</p> <p>VE (%) = 65.0327 - 0.1286 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	65.0327	5.1151	12.7138	30	<.0001	54.5863	75.4791	***																					
Days	-0.1286	0.0430	-2.9885	30	0.0055	-0.2164	-0.0407	**																					




Reg Plot		
Variable	Ad26.COV2.S	
Results	N/A	
Reg Plot	N/A	
Variable	BNT162b2	
Results	<p>Mixed-Effects Model (k = 17; tau<sup>2</sup> estimator: REML)</p> <p>logLik deviance    AIC    BIC    AICc  -57.6048 115.2096 121.2096 123.3337 123.3914</p> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity):    103.7006 (SE = 47.6416)  tau (square root of estimated tau<sup>2</sup> value):            10.1834  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 99.13%  H<sup>2</sup> (unaccounted variability / sampling variability): 115.43  R<sup>2</sup> (amount of heterogeneity accounted for):            68.20%</p> <p>Test for Residual Heterogeneity:  QE(df = 15) = 1755.9344, p-val &lt; .0001</p>	<p>R<sup>2</sup> = 68.2%  VE estimate (%):  68.79 (59.21 to 78.38), p:&lt;.0001  VE reduction estimate (% per month):  -6.423 (-8.898 to -3.948), p:&lt;.0001</p> <p>VE (%) = 68.7937 - 0.2141 day</p>

	<p>Test of Moderators (coefficient 2):  <math>F(df1 = 1, df2 = 15) = 30.6190, p\text{-val} &lt; .0001</math></p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> <th></th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>68.7937</td> <td>4.4963</td> <td>15.3002</td> <td>15</td> <td>&lt;.0001</td> <td>59.2101</td> <td>78.3773</td> <td>***</td> </tr> <tr> <td>Days</td> <td>-0.2141</td> <td>0.0387</td> <td>-5.5334</td> <td>15</td> <td>&lt;.0001</td> <td>-0.2966</td> <td>-0.1316</td> <td>***</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub		intrcpt	68.7937	4.4963	15.3002	15	<.0001	59.2101	78.3773	***	Days	-0.2141	0.0387	-5.5334	15	<.0001	-0.2966	-0.1316	***	
	estimate	se	tval	df	pval	ci.lb	ci.ub																						
intrcpt	68.7937	4.4963	15.3002	15	<.0001	59.2101	78.3773	***																					
Days	-0.2141	0.0387	-5.5334	15	<.0001	-0.2966	-0.1316	***																					
Reg Plot																													
Variable	ChAdOx1 nCov-19																												
Results	<p>Number of studies combined: <math>k = 2</math></p> <table border="1"> <thead> <tr> <th></th> <th>VE</th> <th>95%-CI</th> <th>t</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Random effects model</td> <td>51.4480</td> <td>[-4.9677; 107.8637]</td> <td>11.59</td> <td>0.0548</td> </tr> </tbody> </table> <p>Quantifying heterogeneity:  <math>\tau^2 = 9.6042; \tau = 3.0991; I^2 = 24.2%; H = 1.15</math></p>			VE	95%-CI	t	p-value	Random effects model	51.4480	[-4.9677; 107.8637]	11.59	0.0548	<p><math>I^2 = 24.2%</math>  VE estimate (%):  51.4480 (-4.9677 to 107.8637),  <math>p: 0.0548</math>  VE reduction estimate (% per month):  N/A</p>																
	VE	95%-CI	t	p-value																									
Random effects model	51.4480	[-4.9677; 107.8637]	11.59	0.0548																									

	Test of heterogeneity: Q d.f. p-value 1.32 1 0.2506																									
Reg Plot	N/A																									
Variable	mixture																									
Results	<p>Mixed-Effects Model (k = 3; tau^2 estimator: REML)</p> <p>logLik deviance AIC BIC AICc -5.1995 10.3990 16.3990 10.3990 40.3990</p> <p>tau^2 (estimated amount of residual heterogeneity): 1921.3492 (SE = 2718.1185) tau (square root of estimated tau^2 value): 43.8332 I^2 (residual heterogeneity / unaccounted variability): 99.97% H^2 (unaccounted variability / sampling variability): 2953.42 R^2 (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity: QE(df = 1) = 2953.4221, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2): F(df1 = 1, df2 = 1) = 0.0055, p-val = 0.9527</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>59.9937</td> <td>92.9874</td> <td>0.6452</td> <td>1</td> <td>0.6352</td> <td>-1121.5233</td> <td>1241.5107</td> </tr> <tr> <td>Days</td> <td>-0.0666</td> <td>0.8948</td> <td>-0.0744</td> <td>1</td> <td>0.9527</td> <td>-11.4361</td> <td>11.3030</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub	intrcpt	59.9937	92.9874	0.6452	1	0.6352	-1121.5233	1241.5107	Days	-0.0666	0.8948	-0.0744	1	0.9527	-11.4361	11.3030	<p>R^2 = 0%</p> <p>VE estimate (%): 59.99 (-1121.52 to 1241.51), p:0.6352 VE reduction estimate (% per month): -1.998 (-343.083 to 339.09), p:0.9527</p> <p>VE (%) = 59.9937 - 0.0666 day</p>
	estimate	se	tval	df	pval	ci.lb	ci.ub																			
intrcpt	59.9937	92.9874	0.6452	1	0.6352	-1121.5233	1241.5107																			
Days	-0.0666	0.8948	-0.0744	1	0.9527	-11.4361	11.3030																			

Reg Plot												
Variable	Mixture of mRNA											
Results	<p>Mixed-Effects Model (k = 5; tau<sup>2</sup> estimator: REML)</p> <table border="0"> <tr> <td>logLik</td> <td>deviance</td> <td>AIC</td> <td>BIC</td> <td>AICc</td> </tr> <tr> <td>-13.0663</td> <td>26.1326</td> <td>32.1326</td> <td>29.4284</td> <td>56.1326</td> </tr> </table> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 236.0327 (SE = 231.3246)  tau (square root of estimated tau<sup>2</sup> value): 15.3634  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 98.40%  H<sup>2</sup> (unaccounted variability / sampling variability): 62.33  R<sup>2</sup> (amount of heterogeneity accounted for): 0.00%</p> <p>Test for Residual Heterogeneity:  QE(df = 3) = 147.6486, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 3) = 0.2119, p-val = 0.6766</p>	logLik	deviance	AIC	BIC	AICc	-13.0663	26.1326	32.1326	29.4284	56.1326	<p>R<sup>2</sup> = 0%  VE estimate (%):  76.66 (34.59 to 118.73), p:0.0102  VE reduction estimate (% per month):  -1.119 (-8.862 to 6.621), p:0.6766</p> <p>VE (%) = 76.6635 - 0.0373 day</p>
logLik	deviance	AIC	BIC	AICc								
-13.0663	26.1326	32.1326	29.4284	56.1326								

	<p>Model Results:</p> <pre> estimate  se  tval df  pval  ci.lb  ci.ub intrcpt  76.6635  13.2197  5.7992  3  0.0102  34.5924  118.7346 * Days     -0.0373  0.0811  -0.4604  3  0.6766  -0.2954  0.2207 </pre>	
Reg Plot		
Variable	mRNA-1273	
Results	<p>Mixed-Effects Model (k = 5; tau<sup>2</sup> estimator: REML)</p> <pre> logLik deviance  AIC  BIC  AICc -11.3853  22.7707  28.7707  26.0665  52.7707 </pre> <p>tau<sup>2</sup> (estimated amount of residual heterogeneity): 95.7588 (SE = 92.1843)  tau (square root of estimated tau<sup>2</sup> value): 9.7856  I<sup>2</sup> (residual heterogeneity / unaccounted variability): 94.39%  H<sup>2</sup> (unaccounted variability / sampling variability): 17.84  R<sup>2</sup> (amount of heterogeneity accounted for): 20.38%</p>	<p>R<sup>2</sup> = 20.38%  VE estimate (%):  78.44 (30.98 to 125.9), p:0.0134  VE reduction estimate (% per month):  -16.152 (-53.139 to 20.835), p:0.2588</p> <p>VE (%) = 78.4407 - 0.5384 day</p>

	<p>Test for Residual Heterogeneity:  QE(df = 3) = 22.5681, p-val &lt; .0001</p> <p>Test of Moderators (coefficient 2):  F(df1 = 1, df2 = 3) = 1.9314, p-val = 0.2588</p> <p>Model Results:</p> <table border="1"> <thead> <tr> <th></th> <th>estimate</th> <th>se</th> <th>tval</th> <th>df</th> <th>pval</th> <th>ci.lb</th> <th>ci.ub</th> </tr> </thead> <tbody> <tr> <td>intrcpt</td> <td>78.4407</td> <td>14.9141</td> <td>5.2595</td> <td>3</td> <td>0.0134</td> <td>30.9773</td> <td>125.9041 *</td> </tr> <tr> <td>Days</td> <td>-0.5384</td> <td>0.3874</td> <td>-1.3898</td> <td>3</td> <td>0.2588</td> <td>-1.7713</td> <td>0.6945</td> </tr> </tbody> </table>		estimate	se	tval	df	pval	ci.lb	ci.ub	intrcpt	78.4407	14.9141	5.2595	3	0.0134	30.9773	125.9041 *	Days	-0.5384	0.3874	-1.3898	3	0.2588	-1.7713	0.6945	
	estimate	se	tval	df	pval	ci.lb	ci.ub																			
intrcpt	78.4407	14.9141	5.2595	3	0.0134	30.9773	125.9041 *																			
Days	-0.5384	0.3874	-1.3898	3	0.2588	-1.7713	0.6945																			
Reg Plot	<p>The regression plot displays Vaccine Effectiveness on the y-axis (ranging from 25 to 75) against Time in days on the x-axis (ranging from 20 to 60). A blue line represents the fitted regression model, showing a negative correlation. A grey shaded area around the line indicates the confidence interval. Five data points are plotted as open circles, with approximate coordinates: (22, 55), (30, 72), (35, 65), (42, 55), and (62, 40).</p>																									

Cell is denoted as **green** if meta-regression is performed (i.e., if  $k > 3$ ). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report ( $k = 2$ ). Cell is denoted as **red** if the result has not been reported by any studies ( $k = 0$ ).

## S.10. Detailed Results of Meta-analyses for the ‘Within 3 Months’ Model

Table S15. Detailed Results of meta-analyses for within 3 months model

Variable	k	VED (95%CI)	p-value of VED	Tau2	I2 (95%CI)	p-value of I2	Chi^2	df	p-value of Egger's test
<b>Any Infection</b>									
The Overall Result	22	22% (15% to 29%)	<0,0001	0.0207	98.3% (97.9% to 98.6%)	<0,0001	1214.69	21	0.203724
<i>Study Design Subgroup:</i>									
Cohort	6	35% (14% to 57%)	<0,0001	0.0678	99.6% (99.4% to 99.7%)	<0,0001	1148.18	5	0.245683
Case-control	16	17% (13% to 21%)	<0,0001	0.0041	76.1% (61.4% to 85.3%)	<0,0001	62.88	15	0.811881
<i>Vaccine Subgroup:</i>									
Ad26.COVS2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	8	25% (8% to 41%)	<0,0001	0.0485	98.9% (98.5% to 99.1%)	<0,0001	616.65	7	0.856062
ChAdOx1 nCov-19	1	16% (2% to 30%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	2	27% (-1% to 55%)	<0.0001	0.0407	96.9% (91.8% to 98.8%)	<0.0001	32.17	1	N/A
Mixture of mRNA	7	15% (6% to 24%)	<0.0001	0.0105	79.9% (59% to 90.2%)	<0.0001	29.88	6	0.845442
mRNA-1273	4	25% (4% to 47%)	<0,0001	0.0423	96.8% (94.3% to 98.2%)	<0,0001	94.28	3	0.889649
<b>Severe Infection</b>									
The Overall Result	7	20% (8% to 32%)	<0,0001	0.0193	81.1% (61.9% to 90.6%)	<0,0001	31.8	6	0.919516
<i>Study Design Subgroup:</i>									
Cohort	2	34% (16% to 52%)	0.0525	0.0126	73.4% (0% to 94%)	0.0525	3.76	1	N/A
Case-control	5	13% (5% to 20%)	0.2038	0.0024	32.6% (0% to 74.4%)	0.2038	5.94	4	0.477389
<i>Vaccine Subgroup:</i>									
Ad26.COVS2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	2	22% (9% to 35%)	0.7444	0	0% (0% to 0%)	0.7444	0.11	1	N/A
ChAdOx1 nCov-19	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	1	42% (32% to 52%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	4	12% (3% to 21%)	0.1372	0.0036	45.7% (0% to 81.9%)	0.1372	5.52	3	0.65151
mRNA-1273	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

<b>Symptomatic Infection</b>									
The Overall Result	12	22% (11% to 34%)	<0,0001	0.0371	98.5% (98.1% to 98.8%)	<0,0001	747	11	0.989773
<i>Study Design Subgroup:</i>									
Cohort	2	51% (49% to 53%)	0.5383	0	N/A	0.5383	0.38	1	N/A
Case-control	10	17% (12% to 22%)	<0,0001	0.0043	81.3% (66.7% to 89.5%)	<0,0001	48.11	9	0.844111
<i>Vaccine Subgroup:</i>									
Ad26.COVS2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	5	25% (5% to 46%)	0.0001	0.0504	99.4% (99.1% to 99.5%)	0.0001	616.01	4	0.827264
ChAdOx1 nCov-19	1	16% (2% to 30%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	3	17% (1% to 33%)	<0.0001	0.0177	90.7% (75.6% to 96.5%)	<0.0001	21.51	2	0.842218
mRNA-1273	3	23% (-7% to 54%)	<0,0001	0.0065	97.9% (96% to 98.9%)	<0,0001	94.24	2	0.928712

Abbreviation: k, number of analyses; N/A, not available; VED, vaccine effectiveness difference.



### S.11. Detailed Results of Meta-analyses for the ‘Within 3 Months or More’ Model

Table S16. Detailed Results of meta-analyses for within 3 months or more model

Variable	k	VED (95%CI)	p-value of VED	Tau2	I2 (95%CI)	p-value of I2	Chi^2	df	p-value of Egger’s test
<b>Any Infection</b>									
The Overall Result	28	30% (24% to 37%)	<0.0001	0.0362	97.6% (97% to 98%)	<0.0001	1103.33	27	0.583963
<i>Study Design Subgroup:</i>									
Cohort	6	43% (22% to 64%)	<0.0001	0.0661	99.3% (99% to 99.5%)	<0.0001	765.77	5	0.52177
Case-control	22	27% (21% to 34%)	<0.0001	0.019	93.8% (92% to 95.3%)	<0.0001	336.14	21	0.827997
<i>Vaccine Subgroup:</i>									
Ad26.CO2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	9	40% (28% to 52%)	<0.0001	0.0271	97.7% (97% to 98.3%)	<0.0001	345.71	8	0.666296
ChAdOx1 nCov-19	1	27% (14% to 41%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	2	29% (-4% to 62%)	0.0863	0.0542	96.7% (91% to 98.8%)	<0.0001	30.12	1	N/A
Mixture of mRNA	10	21% (14% to 27%)	<0.0001	0.0067	79% (62% to 88.4%)	<0.0001	42.93	9	0.796208
mRNA-1273	6	36% (22% to 50%)	<0.0001	0.0241	93.3% (88% to 96.2%)	<0.0001	74.36	5	0.291389
<b>Severe Infection</b>									
The Overall Result	9	18% (13% to 23%)	<0.0001	0.0043	88.8% (81% to 93.4%)	<0.0001	71.34	8	0.876591
<i>Study Design Subgroup:</i>									
Cohort	2	35% (13% to 57%)	0.0016	0.0202	80% (14% to 95.3%)	0.0255	4.99	1	N/A
Case-control	7	11% (5% to 17%)	0.0004	0.0014	21.1% (0% to 64.4%)	0.2688	7.6	6	0.305242
<i>Vaccine Subgroup:</i>									
Ad26.CO2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	2	22% (9% to 35%)	0.0008	0	0% (0% to 0%)	0.7444	0.11	1	N/A
ChAdOx1 nCov-19	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	1	46% (34% to 58%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	5	11% (3% to 18%)	0.005	0.0028	41.8% (0% to 78.6%)	0.1425	6.88	4	0.483804
mRNA-1273	1	15% (-24% to 54%)	0.4578	N/A	N/A	N/A	N/A	N/A	N/A

<b>Symptomatic Infection</b>									
The Overall Result	14	37% (29% to 46%)	<0.0001	0.0226	97.1% (96% to 97.8%)	<0.0001	451.64	13	0.755126
<i>Study Design Subgroup:</i>									
Cohort	2	51% (49% to 53%)	0	0	0% (0% to 0%)	0.5383	0.38	1	N/A
Case-control	12	34% (25% to 44%)	<0.0001	0.023	95.5% (94% to 96.8%)	<0,0001	243.29	11	0.444867
<i>Vaccine Subgroup:</i>									
Ad26.CO2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	6	40% (26% to 55%)	<0.0001	0.027	98.5% (98% to 98.9%)	<0.0001	329.82	5	0.652238
ChAdOx1 nCov-19	1	27% (14% to 41%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	3	28% (20% to 36%)	<0.0001	0.0031	61.1% (0% to 88.9%)	0.0767	5.14	2	0.183352
mRNA-1273	4	41% (25% to 56%)	<0.0001	0.0226	94.4% (89% to 97.2%)	<0,0001	53.56	3	0.470046

\*The Egger's test has p-value <0.05 but cannot be an indication of publication bias due to k<10.

Abbreviation: k, number of analyses; N/A, not available; VE, vaccine effectiveness.

## S.12. Sensitivity Analyses for the ‘Within 3 Months’ Model

Figure S1. The result of leave-one-out sensitivity analyses for any infection endpoint in the ‘within 3 months’ model




Figure S2. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months' model





Figure S3. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months' model



### S.13. Sensitivity Analyses for the 'Within 3 Months or More' Model

Figure S4. The result of leave-one-out sensitivity analyses for any infection endpoint in the 'within 3 months or more' model




Figure S5. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months or more' model




Figure S6. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months or more' model

